LL-37 (Cathelicidin) vs Thymosin Alpha-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | Thymosin Alpha-1 |
|---|---|---|
| Dose Range | 500 mcg–1.6 mg | 1.6 mg–3.2 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 2–4 weeks | 4–12 weeks |
| Route | topical | subcutaneous |
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. |
| Best For |
What They Have in Common
LL-37 (Cathelicidin), Thymosin Alpha-1 are both commonly used for:
Which Has Stronger Evidence?
- Recovery & Healing: Thymosin Alpha-1 has stronger research support.
| Goal | LL-37 (Cathelicidin) | Thymosin Alpha-1 |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
LL-37 (Cathelicidin)
- Cathelicidin LL-37 Expression in Human Breast Implant Capsules.
Plastic and reconstructive surgery, 2024
- Salivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV.
Biomedicine hub, 2024
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.
World journal of microbiology & biotechnology, 2023
Thymosin Alpha-1
- Aging and Thymosin Alpha-1.
International journal of molecular sciences, 2025
- Phenotypic drug discovery: a case for thymosin alpha-1.
Frontiers in medicine, 2024
- The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Inflammopharmacology, 2023
Ready to Learn More?
Looking for trusted sources?